Neoadjuvant therapy
Factors Affecting Postoperative Morbidity and Mortality in Patients Who Received Neoadjuvant Therapy for Lung Cancer
... Aim: The aim of this study was to investigate the factors that afect mortal- ity and morbidity (MM) in patients with non-small lung cell cancer (NSCLC) who received Neoadjuvant Therapy (NT) for mediastinal ...
4
Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma.
... preoperative neoadjuvant therapy in high risk RCC patients. The neoadjuvant therapy with targeted drugs are recommended under the following conditions: 1, long length inferior vena cava ...
11
Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer
... to neoadjuvant therapy for triple – negative and Her-2 positive early breast cancer ...to neoadjuvant therapy and long–term survival in patients with triple–negative breast ...
7
The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation.
... Next, we analyzed in detail whether different microcalcification appearances were correlated with the tumor response rate and patterns of change. To the best of our knowledge, no studies have ever explored the role of ...
7
The Effect of Neoadjuvant Therapy on Early Complications of Esophageal Cancer Surgery
... This was a randomized clinical trial carried out between 2009 and 2011 in Ghaem and Omid hospitals, Mashhad, both affiliated to Mashhad University of Medical Sciences. One-hundred patients suffering from esophageal ...
6
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
... thyroid carcinoma. The phase-III trial for RAI- refractory differentiated thyroid cancer (DECISION trial) included 7 patients (3.8%) with locally advanced thyroid cancer in the sorafenib arm (1), however, no specific ...
6
J. Coloproctol. (Rio J.) vol.33 número2
... The number of patients in the sample was dei ned by sample calculation as a minimum of 72 to achieve a signii cance level of 5% in all domains of the EORTC QLQ-C30 and EORTC QLQ- CR38 questionnaires. The analysis of the ...
8
Figure 2 (A) High definition axial T1-weighted MRI post-Gd clearly depicts rectal tumor, with transmural stranding in mesorectal
... after neoadjuvant therapy, still consider cTNM staging as an indicator for such therapy whereas recent studies demonstrate that high definition MRI with accurate staging of CRM, may be a better ...
9
Rev. LatinoAm. Enfermagem vol.18 número4
... Of the 20 registrations of extravasation, it was observed that nine (45%) occurred during the neoadjuvant therapy phase and the consequences registered in medical records were: two (22.2%) reports of ...
7
Rev. Bras. Ginecol. Obstet. vol.35 número5
... with neoadjuvant therapy followed by surgery or with primary surgery ...and neoadjuvant therapy groups, ...the neoadjuvant therapy ...
5
J. Coloproctol. (Rio J.) vol.33 número4
... the neoadjuvant treatment and in the time interval between neoadjuvant therapy and ...between neoadjuvant treatment and surgical resection was predominantly 4 to 8 weeks, the same verii ed by ...
6
J. Coloproctol. (Rio J.) vol.35 número1
... to neoadjuvant therapy in patients who have an increased number of lympho- cytes, in proportion to the total number of neutrophils, and this relationship is summarized by the relationship between ...
5
Sao Paulo Med. J. vol.120 número4
... RESULTS: There was a mean increase of 0.50 ± 1.42% (p = 0.21) of body weight per month of treatment. We noted a negative correlation between metastatic disease and weight gain (r = -0.447, p < 0.0001). In the adjuvant ...
5
Biological and behavioral aspects regarding combined systemic management of alcohol dependence
... he present study involved the clinical therapeutic evaluation of 90 patients with alcohol dependence within a period of 12 months. he patients evaluat- ed in the study were in the iles of the Clinical Psy- chiatric ...
4
Int. braz j urol. vol.36 número1
... In Northern America neoadjuvant chemotherapy before radical cystectomy became standard few years ago. What happens if patients (or their doctors, the medical oncologists who deliver chemotherapy) refuse radical ...
2
Int. braz j urol. vol.36 número1
... Methods: Between 1995 and 2001, 63 patients were evaluated who declined to undergo a planned cystectomy, because they achieved a complete clinical response to neoadjuvant cisplatin-based chemotherapy. Patient, tu- ...
2
Marked cytoreduction of a lymphocyte-rich mediastinal thymoma with neoadjuvant chemotherapy in a cat
... postchemo- therapy excisional biopsy histopathological findings of a higher proportion of epithelial cells to lymphocytes than that of the initial needle biopsy supports the assertion that chemotherapy was ...
7
News-Screen
... were randomly assigned in a 2:1 ratio to receive either evo- locumab (140 mg every 2 weeks or 420 mg monthly) plus standard therapy or standard therapy alone. Patients were followed for a median of 11.1 ...
5
Einstein (São Paulo) vol.15 número4 eins S1679
... After neoadjuvant chemotherapy, the patient underwent surgical resection of the mass, followed by pathological examination, which confirmed a primary mediastinal yolk sac tumor, a nonseminomatous subtype of germ ...
4
Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
... and therapy- related elements was well balanced between groups, it would be relatively safe to conclude that pretreatment anemia was a predictor of response to ...
13